HC Wainwright Issues Optimistic Estimate for OLMA Earnings

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) – Equities researchers at HC Wainwright boosted their Q1 2025 EPS estimates for shares of Olema Pharmaceuticals in a report released on Wednesday, March 19th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings per share of ($0.59) for the quarter, up from their previous estimate of ($0.64). HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Olema Pharmaceuticals’ current full-year earnings is ($2.33) per share. HC Wainwright also issued estimates for Olema Pharmaceuticals’ Q2 2025 earnings at ($0.70) EPS, Q3 2025 earnings at ($0.82) EPS, Q4 2025 earnings at ($0.92) EPS, FY2025 earnings at ($3.03) EPS, FY2026 earnings at ($3.86) EPS, FY2027 earnings at ($3.60) EPS and FY2028 earnings at ($3.10) EPS.

Separately, Oppenheimer restated an “outperform” rating and issued a $25.00 price target (down previously from $30.00) on shares of Olema Pharmaceuticals in a research note on Wednesday.

Olema Pharmaceuticals Stock Performance

Olema Pharmaceuticals stock opened at $4.12 on Friday. Olema Pharmaceuticals has a fifty-two week low of $3.94 and a fifty-two week high of $16.62. The firm has a 50 day moving average price of $5.11 and a 200 day moving average price of $8.40. The company has a market capitalization of $236.07 million, a PE ratio of -1.88 and a beta of 2.11.

Olema Pharmaceuticals (NASDAQ:OLMA) last posted its earnings results on Tuesday, March 18th. The company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.12.

Institutional Investors Weigh In On Olema Pharmaceuticals

Several institutional investors have recently modified their holdings of the company. Charles Schwab Investment Management Inc. lifted its position in shares of Olema Pharmaceuticals by 0.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 332,950 shares of the company’s stock worth $1,941,000 after purchasing an additional 2,189 shares during the last quarter. EP Wealth Advisors LLC lifted its position in shares of Olema Pharmaceuticals by 5.2% during the 3rd quarter. EP Wealth Advisors LLC now owns 48,655 shares of the company’s stock worth $581,000 after purchasing an additional 2,407 shares during the last quarter. Boothbay Fund Management LLC lifted its position in shares of Olema Pharmaceuticals by 10.8% during the 4th quarter. Boothbay Fund Management LLC now owns 31,226 shares of the company’s stock worth $182,000 after purchasing an additional 3,056 shares during the last quarter. Virtus ETF Advisers LLC lifted its position in shares of Olema Pharmaceuticals by 43.1% during the 4th quarter. Virtus ETF Advisers LLC now owns 10,579 shares of the company’s stock worth $62,000 after purchasing an additional 3,185 shares during the last quarter. Finally, ProShare Advisors LLC lifted its position in shares of Olema Pharmaceuticals by 30.2% during the 4th quarter. ProShare Advisors LLC now owns 14,226 shares of the company’s stock worth $83,000 after purchasing an additional 3,298 shares during the last quarter. 91.78% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Olema Pharmaceuticals news, major shareholder Bain Capital Life Sciences Inv purchased 300,000 shares of the company’s stock in a transaction on Wednesday, January 8th. The stock was acquired at an average price of $5.76 per share, for a total transaction of $1,728,000.00. Following the completion of the purchase, the insider now directly owns 7,800,000 shares in the company, valued at approximately $44,928,000. The trade was a 4.00 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 19.40% of the company’s stock.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.